Tiotropium 18 μg

DRUG5 trials

Sponsors

Novartis Pharmaceuticals, AstraZeneca

Conditions

AsthmaChronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)

Phase 1

Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPD

CompletedNCT02059434

AstraZenecaAsthma, Chronic Obstructive Pulmonary Disease (COPD)

Start: 2013-09-01End: 2014-10-06Updated: 2019-06-21

Phase 3

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

CompletedNCT00846586

Novartis PharmaceuticalsChronic Obstructive Pulmonary Disease (COPD)

Start: 2009-03-31End: 2010-03-31Updated: 2011-08-18

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

CompletedNCT00877383

Novartis PharmaceuticalsChronic Obstructive Pulmonary Disease (COPD)

Start: 2009-04-30End: 2010-02-28Updated: 2011-08-25

A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT00900731

Novartis PharmaceuticalsChronic Obstructive Pulmonary Disease

Start: 2009-06-30End: 2010-03-31Updated: 2011-08-19

Comparison of the Effects of Indacaterol and Tiotropium on Inspiratory Capacity

CompletedNCT00999908

Novartis PharmaceuticalsChronic Obstructive Pulmonary Disease

Start: 2009-10-31End: 2010-03-31Updated: 2016-02-17

Related Papers

Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison.

2012-04-27113 citations

Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium.

2011-10-2723 citations